Back to School: How biopharma can reboot drug development. Access exclusive analysis here
CELG raised $250.9 million through the sale of 2.48 million shares at $101 per share in its follow-on
Sign in to your BioCentury account to access your content.
Get a two-week free trial subscription to BioCentury